Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016

  • ID: 3832326
  • Drug Pipelines
  • 63 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Grifols, S.A.
  • Kedrion S.p.A.
  • Omeros Corporation
  • MORE
Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016

Summary

‘Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Review, H2 2016’, provides in depth analysis on Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted pipeline therapeutics.

The report provides comprehensive information on the Plasminogen (Plasmin or PLG or EC 3.4.21.7) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Plasminogen (Plasmin or PLG or EC 3.4.21.7)
- The report reviews Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Plasminogen (Plasmin or PLG or EC 3.4.21.7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Plasminogen (Plasmin or PLG or EC 3.4.21.7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Grifols, S.A.
  • Kedrion S.p.A.
  • Omeros Corporation
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Plasminogen (Plasmin or PLG or EC 3.4.21.7) Overview

Therapeutics Development

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Stage of Development

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Therapy Area

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Indication

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Products under Development by Companies

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Companies Involved in Therapeutics Development

Bayer AG

Bharat Biotech International Limited

F. Hoffmann-La Roche Ltd.

Grifols, S.A.

Hyundai Pharmaceutical Co., Ltd.

Kedrion S.p.A.

Nostrum Pharmaceuticals, LLC

Omeros Corporation

ProMetic Life Sciences Inc.

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Drug Profiles

alteplase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-616 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plasminogen (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plasminogen (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plasminogen (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Prourokinase - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Plasminogen for Rare Bleeding Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SMRX-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAL-0500018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THR-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMS-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tranexamic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTS-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Dormant Projects

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Discontinued Products

Plasminogen (Plasmin or PLG or EC 3.4.21.7) - Featured News & Press Releases

Jun 13, 2016: ProMetic plasminogen granted Fast Track designation by the US FDA

May 11, 2016: Positive response in kidney and urinary tract to ProMetic plasminogen treatment in a plasminogen deficient patient under an expanded access protocol in the USA

May 10, 2016: Major new global study identifies a safer treatment of acute stroke

May 03, 2016: Prometic announces successful treatment of a plasminogen deficient patient under an expanded access (compassionate use) protocol in the USA

Feb 18, 2016: Clot-busting therapy reduces mortality in deadliest form of stroke

Dec 07, 2015: ProMetic's plasminogen demonstrates rapid therapeutic response in second clinical case

Nov 04, 2015: Prometic’S Plasminogen Drug Successfully Used to Treat Plasminogen Deficient Infant in Critical Condition

Aug 10, 2015: Prometic Successfully Completes First Dosing In Plasminogen Deficient Patients

Aug 04, 2015: European Commission Grants Orphan Drug Designation to ProMetic's Plasma-Derived Plasminogen Drug

Jul 23, 2015: MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke

Oct 28, 2014: ProMetic's Plasminogen IND and Clinical Program Cleared by FDA

Aug 22, 2014: MHRA To Review Ischemic Stroke Drug

Feb 13, 2014: CSIR Developed Clot Specific Streptokinase Enters into Phase-2 Human Clinical Trials

Jun 25, 2013: Kedrion Announces Plasminogen clinical study now started on drug for treatment of ligneous conjunctivitis

Feb 28, 2013: Mitsubishi Tanabe Pharma And Kyowa Hakko Kirin Receive Japanese Approval For Time-Window Extension Of Thrombolytic Agents GRTPA And Activacin

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 63List of Tables

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Bayer AG, H2 2016

Pipeline by Bharat Biotech International Limited, H2 2016

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Pipeline by Grifols, S.A., H2 2016

Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016

Pipeline by Kedrion S.p.A., H2 2016

Pipeline by Nostrum Pharmaceuticals, LLC, H2 2016

Pipeline by Omeros Corporation, H2 2016

Pipeline by ProMetic Life Sciences Inc., H2 2016

Dormant Projects, H2 2016

Dormant Projects (Contd..1), H2 2016

Discontinued Products, H2 2016 49List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Grifols, S.A.
  • Kedrion S.p.A.
  • Omeros Corporation
  • MORE
According to our recently published report 'Plasminogen – Pipeline Review, H2 2016'; Plasminogen (Plasmin or PLG or EC 3.4.21.7) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies.

Furthermore, the publisher says; Plasminogen (Plasmin or PLG or EC 3.4.21.7) Plasminogen (PLG) is a glycoprotein synthesized in the liver and it circulates in the blood. It is the precursor of plasmin. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. It also cleaves fibrin, thrombospondin and von Willebrand factor. It plays an important role in tissue remodeling and tumor invasion.

The report 'Plasminogen – Pipeline Review, H2 2016' outlays comprehensive information on the Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Plasminogen (Plasmin or PLG or EC 3.4.21.7) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 2, 2 and 4 respectively.
Note: Product cover images may vary from those shown
5 of 6
Bayer AG
Bharat Biotech International Limited
F. Hoffmann-La Roche Ltd.
Grifols, S.A.
Hyundai Pharmaceutical Co., Ltd.
Kedrion S.p.A.
Nostrum Pharmaceuticals, LLC
Omeros Corporation
ProMetic Life Sciences Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll